Sunitinib
Sunitinib
复制标题
DOI：
10.1007/978-3-642-01222-8_6
复制
发表时间：
2010-01-01
期刊：
影响因子：
--
通讯作者：
Kollmannsberger, Christian
中科院分区：
文献类型：
--
作者：
Heng, Daniel Y. C.;Kollmannsberger, Christian
舒尼替尼是一种口服多激酶抑制剂，可阻断血管内皮生长因子受体（VEGFR）、血小板衍生生长因子受体（PDGFR）α和β、c-kit和其他受体。这些属性已被证明是有效的治疗转移性肾细胞癌（RCC）和不可切除的胃肠道间质瘤（GIST）。大多数副作用，包括高血压、手足综合征和腹泻，通常都可以很好地控制。临床试验正在进行中，以确定舒尼替尼在其他肿瘤类型中的疗效，包括转移性乳腺癌，结直肠癌和肺癌。本章将详细介绍导致舒尼替尼在转移性RCC和晚期GIST中广泛使用的关键III期临床试验结果的临床前数据。
Sunitinib is an oral multikinase inhibitor that blocks the vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) alpha and beta, c-kit, and other receptors. These attributes have proven to be efficacious in the treatment of metastatic renal cell carcinoma (RCC) and unresectable gastrointestinal stromal tumors (GIST). Most side effects, including hypertension, hand-foot syndrome, and diarrhea are generally well manageable. Clinical trials are underway to determine the efficacy of sunitinib in other tumor types including metastatic breast, colorectal, and lung cancers. This chapter will detail the preclinical data leading to the results of the pivotal phase III clinical trials that have led to the widespread use of sunitinib in metastatic RCC and advanced GIST.